NanoViricides, Inc. Presents at the Global Pharma R&D Summit

WEST HAVEN, Conn.--(BUSINESS WIRE)--Oct 23, 2007 - NanoViricides, Inc. (OTC BB: NNVC) (the "Company"), presented additional preclinical data at the 4th Annual Global Pharma R&D Summit in Boston on October 22nd (http://www.globalpharmasummit.com/programme.asp).

Dr. Anil R. Diwan, Company President, presented the current results of nanoviricides drug development work against multiple viruses. Significant reduction in lung viral load in influenza H1N1 animal study was described among the new datasets. The one log viral load reduction was especially significant because the treatment was given as a tail vein injection, said Dr. Diwan. The reduction in viral load was corroborated with additional biological tests as well. He also presented the data which indicate that FluCide(TM)-I and FluCide-HP(TM) may be as much as 10 times (1,000%) to 16 times (1,600%) superior to current treatment standard, oseltamivir (active ingredient of Tamiflu(R), Roche) against common influenza, and even better against bird flu (H5N1).

"The era of classical antiviral therapies is coming to an end, with the introduction of highly efficacious nanoviricide drug candidates," he declared. "Influenza virus cannot escape FluCide-I through mutations, reassortments or recombinations, because of the particular ligand we have chosen, based on sialic acid," he reiterated in front of the scientific audience in response to a question.

The Global Pharma R&D Summit brings together decision makers from a number of big and mid-size pharmaceutical companies, as well as new technology companies, and features invited presentations.

About NanoViricides:

NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide(TM) class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H5N1 bird flu, seasonal influenza, HIV, hepatitis C, rabies, dengue fever, among others.

NanoViricides, Inc. is a development stage company that is creating special purpose nanomaterials for viral therapy. This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Forward-looking statements involve risks and uncertainties. Actual events could differ materially and substantially from those projected herein and depend on a number of factors certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance, or achievements of the company to be different from those expressed or implied including the success of the Company's research and development strategy, the availability of adequate financing, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process, described in the "Management's Discussion and Analysis" section of the Company's Form 10-KSB and other reports and filings with the Securities and Exchange Commission.

Contact

NanoViricides, Inc.
Amanda Schuon, 310-550-7200
info@nanoviricides.com

Posted: October 2007

View comments

Hide
(web3)